BACKGROUND AND AIMS: To assess the harms of colonoscopy in a real world colorectal cancer screening programme with faecal occult blood test. METHODS: Retrospective cohort study of all colonoscopies performed in patients aged 50-74 for a positive guaiac-based faecal occult blood test between September 2003 and February 2010 within the screening programme in progress in Alsace (France). Adverse events were recorded through prospective voluntary reporting by gastroenterologists and retrospective postal surveys addressed to persons screened and their general practitioners. RESULTS: Of 10,277 colonoscopies, 250 adverse events were recorded, 48 (4.7 ‰, 95% CI 3.4-6.0) of them being moderate or severe, mainly 10 (1.0 ‰, 95% CI 0.4-1.6) perforations and 31 (3.0 ‰, 95% CI 2.0-4.1) bleeding. 91.7% of moderate and severe adverse events were the result of a therapeutic procedure. Of 103 serious adverse events, eight (7.8%) were considered preventable. Gastroenterologists reported 52.2% of moderate and severe adverse events. A mild adverse event or an incident was reported in up to 97.0 ‰ (95% CI 83.2-110.7) colonoscopies. CONCLUSION: The harms of colonoscopy were underestimated in all randomized controlled trials on colorectal cancer screening with faecal occult blood test. They are greater in a real world programme, estimated at 7.5 major and 100 minor adverse events per 1000 colonoscopies.
BACKGROUND AND AIMS: To assess the harms of colonoscopy in a real world colorectal cancer screening programme with faecal occult blood test. METHODS: Retrospective cohort study of all colonoscopies performed in patients aged 50-74 for a positive guaiac-based faecal occult blood test between September 2003 and February 2010 within the screening programme in progress in Alsace (France). Adverse events were recorded through prospective voluntary reporting by gastroenterologists and retrospective postal surveys addressed to persons screened and their general practitioners. RESULTS: Of 10,277 colonoscopies, 250 adverse events were recorded, 48 (4.7 ‰, 95% CI 3.4-6.0) of them being moderate or severe, mainly 10 (1.0 ‰, 95% CI 0.4-1.6) perforations and 31 (3.0 ‰, 95% CI 2.0-4.1) bleeding. 91.7% of moderate and severe adverse events were the result of a therapeutic procedure. Of 103 serious adverse events, eight (7.8%) were considered preventable. Gastroenterologists reported 52.2% of moderate and severe adverse events. A mild adverse event or an incident was reported in up to 97.0 ‰ (95% CI 83.2-110.7) colonoscopies. CONCLUSION: The harms of colonoscopy were underestimated in all randomized controlled trials on colorectal cancer screening with faecal occult blood test. They are greater in a real world programme, estimated at 7.5 major and 100 minor adverse events per 1000 colonoscopies.
Authors: Ankie Reumkens; Eveline J A Rondagh; C Minke Bakker; Bjorn Winkens; Ad A M Masclee; Silvia Sanduleanu Journal: Am J Gastroenterol Date: 2016-06-14 Impact factor: 10.864
Authors: Amit G Singal; Samir Gupta; Celette Sugg Skinner; Chul Ahn; Noel O Santini; Deepak Agrawal; Christian A Mayorga; Caitlin Murphy; Jasmin A Tiro; Katharine McCallister; Joanne M Sanders; Wendy Pechero Bishop; Adam C Loewen; Ethan A Halm Journal: JAMA Date: 2017-09-05 Impact factor: 56.272
Authors: Omair Atiq; Jasmin Tiro; Adam C Yopp; Adam Muffler; Jorge A Marrero; Neehar D Parikh; Caitlin Murphy; Katharine McCallister; Amit G Singal Journal: Hepatology Date: 2016-12-19 Impact factor: 17.425
Authors: Roland Valori; George Cortas; Thomas de Lange; Omer Salem Balfaqih; Marjon de Pater; Pierre Eisendrath; Premysl Falt; Irfan Koruk; Akiko Ono; Nadan Rustemović; Erik Schoon; Andrew Veitch; Carlo Senore; Cristina Bellisario; Silvia Minozzi; Cathy Bennett; Michael Bretthauer; Mario Dinis-Ribeiro; Dirk Domagk; Cesare Hassan; Michal F Kaminski; Colin J Rees; Cristiano Spada; Raf Bisschops; Mathew Rutter Journal: United European Gastroenterol J Date: 2018-11-04 Impact factor: 4.623
Authors: Ellen M Mikkelsen; Mette Kielsholm Thomsen; Julie Tybjerg; Lennart Friis-Hansen; Berit Andersen; Jens Christian Riis Jørgensen; Gunnar Baatrup; Sisse H Njor; Frank Mehnert; Morten Rasmussen Journal: Clin Epidemiol Date: 2018-11-13 Impact factor: 4.790